EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Remimazolam for Precision Sedation and Anaesthesia in Vulnerable Populations: A Narrative Review of Pharmacological Mechanisms, Stratified Clinical Evidence, and Individualised Perioperative Strategies

Guanghan Wu, Jiaxue Zhang, Yufei Li, Yitong Zhou, Jianbo Wu, Zhaoyang Xiao iD

Drug Design, Development and Therapy · 2026-10 · Volume 20 · 1-14

DOI: 10.2147/dddt.s637421 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026-10. Verfasst von Guanghan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027, People's Republic of China. Hauptthemen laut MEDLINE: Benzodiazepines, Hypnotics and Sedatives, Anesthesia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sedation and anaesthesia in vulnerable populations are complicated by altered pharmacokinetics, variable pharmacodynamic sensitivity, and limited physiological reserve. The extent of these differences depends on the underlying condition, disease severity, comorbidity, and treatment setting. These issues are common in older adults, patients with obesity or obstructive sleep apnoea, organ dysfunction, cardiovascular vulnerability, critical illness, and neurological or psychiatric comorbidity. Conventional sedatives may be poorly tolerated in these settings. Propofol can cause hypotension and respiratory depression. Midazolam may lead to delayed recovery and accumulation. Dexmedetomidine may be limited by bradycardia and slow onset. Remimazolam is an ultra-short-acting benzodiazepine that undergoes rapid carboxylesterase-mediated hydrolysis and can be antagonised with flumazenil. This narrative review examines its pharmacology, clinical evidence, and practical use across nine vulnerable populations. The synthesis prioritised population-specific clinical studies, pharmacokinetic studies, comparative trials, systematic reviews, and major guidelines. For short procedures, the most consistent evidence concerns older adults and haemodynamically vulnerable patients, in whom remimazolam has often been associated with less hypotension than propofol and faster recovery than midazolam. These findings are based mainly on short-term physiological and recovery outcomes. Evidence in mild to moderate hepatic or renal dysfunction is supportive but remains sparse in severe disease. Data for obesity or obstructive sleep apnoea, prolonged ICU sedation, paediatric care, obstetrics, and neurological or psychiatric vulnerability are limited or indirect. Remimazolam should therefore be considered according to the clinical objective, the expected duration and depth of sedation, opioid exposure, airway risk, and organ reserve. Its pharmacological advantages have not yet been shown to improve delirium, cognition, mechanical ventilation, functional recovery, or long-term safety. Further studies should focus on population-specific dosing models and patient-centred outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodiazepinesHypnotics and SedativesAnesthesiaHumansVulnerable Populations

Stichwörter der Autor:innen

general anaesthesiaperioperative managementprecision anaesthesiaprocedural sedationremimazolamspecial populations

Substanzen

remimazolamBenzodiazepinesHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Anesthesiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027, People's Republic of China.
  • Department of Anesthesiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Institute of Anesthesia and Respiratory Critical Medicine, Shandong Pr…

ORCID-Profile: Zhaoyang Xiao

Zitieren

APA

Wu, G., Zhang, J., Li, Y., Zhou, Y., Wu, J., & Xiao, Z. (2026). Remimazolam for Precision Sedation and Anaesthesia in Vulnerable Populations: A Narrative Review of Pharmacological Mechanisms, Stratified Clinical Evidence, and Individualised Perioperative Strategies. Drug Design, Development and Therapy, Volume 20, 1-14. https://doi.org/10.2147/dddt.s637421

Vancouver

Wu G, Zhang J, Li Y, Zhou Y, Wu J, Xiao Z. Remimazolam for Precision Sedation and Anaesthesia in Vulnerable Populations: A Narrative Review of Pharmacological Mechanisms, Stratified Clinical Evidence, and Individualised Perioperative Strategies. Drug Design, Development and Therapy. 2026;Volume 20:1-14. doi:10.2147/dddt.s637421

BibTeX
@article{Wu2026,
  author = {Wu, Guanghan and Zhang, Jiaxue and Li, Yufei and Zhou, Yitong and Wu, Jianbo and Xiao, Zhaoyang},
  title = {Remimazolam for Precision Sedation and Anaesthesia in Vulnerable Populations: A Narrative Review of Pharmacological Mechanisms, Stratified Clinical Evidence, and Individualised Perioperative Strategies},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--14},
  doi = {10.2147/dddt.s637421}
}
Kostenlos starten →